Entrada Therapeutics (TRDA) Change in Acquisitions & Divestments (2022 - 2026)

Entrada Therapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $38.9 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 54.79% year-over-year to $38.9 million; the TTM figure through Mar 2026 stood at $212.4 million (down 43.38% YoY), while the FY2025 annual figure was $259.5 million, down 37.19% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $38.9 million, down from $47.4 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $123.9 million in Q1 2024, with the low at $1.7 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $63.0 million (2023), against an average of $62.5 million.
• The sharpest annual moves came in 2023 and 2025: Change in Acquisitions & Divestments jumped 3575.61% in 2023, then slumped 60.01% in 2025.
• Entrada Therapeutics' Change in Acquisitions & Divestments stood at $19.5 million in 2022, then jumped by 456.62% to $108.5 million in 2023, then rose by 9.17% to $118.5 million in 2024, then plunged by 60.01% to $47.4 million in 2025, then slipped by 18.0% to $38.9 million in 2026.
• Business Quant data shows TRDA's Change in Acquisitions & Divestments at $38.9 million in Q1 2026, $47.4 million in Q4 2025, and $75.5 million in Q3 2025.